Group 1 - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 0.95% on February 5, with a trading volume of 4.106 billion yuan [1] - The fund's shares increased by 517 million, bringing the total shares to 20.217 billion, with a total increase of 970 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 25.534 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the China Securities Hong Kong Innovative Drug Index (in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its establishment on July 1, 2022, the fund has achieved a return of 26.29%, while the return over the past month is -0.84% [1]
2月5日港股创新药ETF（513120）份额增加5.17亿份
Xin Lang Cai Jing·2026-02-06 01:09